MYOF and gastric cancer: Kaplan–Meier analysis of gastric cancer patients in the GEO database showed that high expression of MYOF was significantly associated with poorer overall survival (OS; HR = 1.80, 95% CI 1.52–2.13, P<0.0001; Figure 2A), progression-free survival (PFS; HR = 1.91; 95% CI 1.56–2.35, P<0.0001; Figure 2B) and post-progression survival (PPS; HR = 2.36, 95% CI 1.88–2.98, P<0.0001; Figure 2C).